Christi Shaw, JPM19 (Credit: Jeff Rumans)

Gilead­'s Kite keeps adding to CAR-T Yescar­ta's bag of tricks with FDA ap­proval in fol­lic­u­lar lym­phoma — a first

Sev­er­al months af­ter cre­at­ing the first com­mer­cial CAR-T port­fo­lio with the FDA’s nod for Tecar­tus, Gilead’s Kite has racked up a sought-af­ter new in­di­ca­tion for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.